THE INFECTION CAUSED BY HAEMOPHILUS INFLUENZAE TYPE B: THE MODERN VISION OF VACCINE PREVENTION

Download full text PDF
Issue: 
10
Year: 
2017

E.L. Salimova Head of the Department «Combined Vaccines», Saint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations of Federal Medical and Biologic Agency E-mail: e.l.salimova@spbniivs.ru A.D. Konon Ph.D. (Eng.), Saint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations of Federal Medical and Biologic Agency V.P. Truhin Ph.D. (Juridical), Saint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations of Federal Medical and Biologic Agency S.V. Petrovskii First Deputy Director, Saint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations of Federal Medical and Biologic Agency I.V. Krasilnikov Dr.Sc. (Biol.), Saint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations of Federal Medical and Biologic Agency

The review summarizes some information on diseases caused by Haemophilus influenzae type b (Hib), and vaccines for their pre-vention. The most common invasive diseases caused by Hib before the introduction of vaccination were epiglottitis, pneumonia, arthritis, cellulitis, meningitis. The history of the development of an effective Hib vaccine is given beginning with the use of the first vaccine. The main active ingredient of the first vaccine was the capsular polysaccharide polyribosylribitol phosphate (PRP), synthesized by Hib and re-sponsible for the virulence of this bacterium. Today, for the prevention of infections caused by Hib, conjugate vaccines are used, which in-clude PRP connecting with a carrier protein (the membrane protein complex of Neisseria meningitides and tetanus toxoid). Conjugation leads to a change in the immune response from T-independent to T-dependent, which makes the vaccine effective for children under the age of 2 years. The review provides a summary of some of the modern vaccines used for immunization against Hib. Both mono-and com-bination vaccines manufactured in the United States, the Russian Federation, the European Union are considered. In addition, the effec-tiveness of vaccines for different age groups is considered, as well as the vaccination schedule. The world situation and prospects of pro-duction of polysaccharide vaccines in the territory of the Russian Federation are indicated. Currently, more than 190 countries in the world have included a prophylactic vaccine against Hib in their national calendar, and the number of such states is increasing every year. Accord-ing to the National calendar of preventive vaccinations in the Russian Federation vaccination against infection caused by Hib is carried out only for children from the risk group, which is due to the lack of a sufficient amount of own (local) production vaccines in Russian Federa-tion. Therefore, the relevant objective is the development and introduction of a local Hib-vaccine.

Keywords: 
Haemophilus influenzae type b
vaccine
infection
meningitis
prevention.

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.